We have previously created a potent DNA vaccine encoding calreticulin linked to the human papillomavirus (HPV) oncogenic protein E7 (CRT/E7). While treatment with the CRT/E7 DNA vaccine generates significant tumor-specific immune responses in vaccinated mice, the potency with the DNA vaccine could potentially be improved by co-administration of a histone deacetylase inhibitor (HDACi) as HDACi has been shown to increase the expression of MHC class I and II molecules. Thus, we aimed to determine whether coadministration of a novel HDACi, AR-42, with therapeutic HPV DNA vaccines could improve the activation of HPV antigen-specific CD8 + T cells, resulting in potent therapeutic antitumor effects. To do so, HPV-16 E7-expressing murine Electronic supplementary material The online version of this article
TC-1 tumor-bearing mice were treated orally with AR-42 and/or CRT/E7 DNA vaccine via gene gun. Mice were monitored for E7-specific CD8 + T cell immune responses and antitumor effects. TC-1 tumor-bearing mice treated with AR-42 and CRT/E7 DNA vaccine experienced longer survival, decreased tumor growth, and enhanced E7-specific immune response compared to mice treated with AR-42 or CRT/E7 DNA vaccine alone. Additionally, treatment of TC-1 cells with AR-42 increased the surface expression of MHC class I molecules and increased the susceptibility of tumor cells to the cytotoxicity of E7-specific T cells. This study indicates the ability of AR-42 to significantly enhance the potency of the CRT/E7 DNA vaccine by improving tumorspecific immune responses and antitumor effects. Both AR-42 and CRT/E7 DNA vaccines have been used in independent clinical trials; the current study serves as foundation for future clinical trials combining both treatments in cervical cancer therapy.
Introduction
Cervical cancer is one of the leading causes of death in women worldwide. A recent estimate indicates that there are approximately 529,800 cases of cervical cancer and 275,100 mortalities annually [1] . While therapeutic techniques such as chemotherapy, radiotherapy, and surgery are currently used to treat cervical cancer, the 5-year survival rates for advanced cervical cancer remain low [2] . These alarming statistics validate the demand for novel therapeutic techniques to battle cervical cancer.
DNA vaccines against human papillomavirus (HPV)-associated cervical cancer represent a unique opportunity for cancer vaccine development. It is now clear that two HPVencoded oncogenic proteins, E6 and E7, are responsible for the malignant transformation of cervical cancer and are constantly expressed in HPV-associated cancer cells. Therefore, HPV E6 and E7 represent true tumor-specific antigens and are ideal targets for developing cancer immunotherapy to control cervical cancer. Furthermore, because E6 and E7 represent foreign proteins, their use in therapeutic vaccines does not have issues related to immune tolerance. In the past, we have created a potent DNA vaccine encoding HPV-16 E7 linked to calreticulin (CRT/E7), which enhances antigen processing associated with MHC class I antigen presentation [3, 4] . Vaccination with the chimeric CRT/E7 DNA vaccine generates a significant E7-specific CD8 + T cell-mediated immune response as well as a strong antitumor effect against an E7-expressing murine tumor model, TC-1, demonstrating the successful application of the HPV oncoprotein in generating a tumor-specific immune response [5] . The encouraging results from preclinical models have led to several ongoing clinical trials using clinical grade CRT/E7 DNA vaccine [6, 7] . Although the CRT/E7 DNA vaccine is a promising therapeutic cancer vaccine, DNA vaccine efficacy tends to be limited by the low expression of the DNA-encoded protein. To resolve this issue, treatments using multiple therapeutic modalities may be used.
Attractive supplementary therapeutic techniques may target and inhibit biological functions that promote tumor development. One such target is histone deacetylase (HDAC), an enzyme responsible for the deacetylation of histones whose inhibition causes hyper-acetylation of core histones, leading to the expression of suppressed genes and regulation of abnormal cell growth [8] . Currently, 18 types of HDACi are known, which fall into three different classes based on their homology to yeast [9] . In addition to promoting the expression of suppressed genes and regulating abnormal cell growth, HDACi may contribute to cancer control by histone-independent mechanisms by modifying the acetylation of non-histone proteins such as p53 [10] and heat shock protein-90 [11] . These mechanisms produce antitumor effects, including induced differentiation, cell growth arrest, and an increase in apoptosis [12, 13] .
AR-42, the novel HDACi used in the current study, is a phenylbutyrate-based, hydroxamate-tethered short-chain fatty acid [14] . The efficacy of AR-42 proves to be dependent on contact with the zinc cation in the active site of the HDAC enzyme. The presence of a Zn 2+ -chelating motif, hydroxamic acid, in AR-42 permits its contact with the HDAC active site [15] . Furthermore, AR-42 has a half-maximal inhibitory concentration in the nanomolar range and a consequently high inhibition efficacy [15] . As such, the optimized structure of AR-42 causes it to be a potent inhibitor of HDACs. AR-42 is similar in structure to suberoylanilide hydroxamic acid (SAHA), also known as Vorinostat, which is an FDAapproved HDACi used in the treatment of cutaneous T cell lymphoma [16] . Nevertheless, AR-42 was shown to have greater potency and antitumor effects against multiple myeloma [17] , lung cancer [18] , and prostate cancer [14] , in cell culture systems, as well as in hepatocellular carcinoma [19] than clinically available SAHA. Thus, AR-42 is an ideal candidate to supplement anticancer therapies.
HDACi represents a great opportunity for boosting the potency of DNA vaccines. Previous studies have found that HDACi enhances the antitumor effects of DNA vaccines in preclinical models by enhancing the expression of the protein/antigen encoded by the DNA vaccine [20, 21] . Furthermore, it has been shown that cells treated with HDACi can lead to the upregulation of MHC class I and II molecules [22] . This suggests that tumor cells may become more susceptible to tumor-specific CD8 + T cell immunotherapy following treatment with an HDACi. Taken together, HDACi may enhance DNA vaccine potency through improved expression of the DNA transfect cell as well as increase the susceptibility of tumor cells to killing by tumorspecific CD8 + T cells generated by the DNA vaccine. In the current study, we intended to demonstrate whether AR-42 could further enhance CRT/E7 DNA vaccine potency. We tested the potency of the synergistic effect of AR-42 administered orally and CRT/E7 DNA vaccine administered intradermally via gene gun in TC-1 tumor-bearing mice. Furthermore, we examined the ability of AR-42 to enhance the DNA vaccine compared to the two clinically available HDACi, SAHA and romidepsin. We showed that treatment with AR-42 could significantly increase the E7-specific CD8 + T cell immune responses and the antitumor effects generated by CRT/E7 DNA vaccination. Because CRT/E7 DNA vaccine and AR-42 have been separately used clinically, our data serve as an important basis for future clinical translation.
Materials and methods

Mice
Five-to 8-week-old female C57BL/6 mice were purchased from the National Cancer Institute (Frederick, MD) and kept in the oncology animal facility of the Johns Hopkins Hospital (Baltimore, MD). All of the animal procedures were done according to approved protocols and in accordance with recommendations for the proper use and care of laboratory animals.
Cell lines
Primary C57BL/6 mouse lung epithelial cells were cotransformed with HPV-16 E6 and E7 and an activated ras oncogene, as previously described [23] , to generate the TC-1 cells. The generation and characteristics of the MHC class I downregulated tumor cell line TC-1 P3 (A15) have been previously described [24] , as well as the E7-specific CD8 + T cell line [25] . The dendritic cell (DC) cell line DC2.4 was a gift from Dr. K.L. Rock [26] . TC-1, TC-1 P3 (A15) tumor cells, and DC2.4 cells were grown in RPMI 1640 supplemented with 10 % fetal bovine serum, 50 U/mL penicillin/streptomycin, 2 mM L-glutamine, 1 mM sodium pyruvate, and 2 mM nonessential amino acids and 2-mercaptoethanol (50 μM) at 37°C in a 5 % CO 2 atmosphere.
DNA constructs
The generation of the DNA vaccine encoding CRT and E7 was described previously [5] . Briefly, for the generation of pcDNA3-CRT, CRT was first amplified by PCR using rabbit CRT cDNA as the template [27] and the primers 5′-CCGG TCTAGAATGCTGCTCCCTGTGCCGCT-3′ and 5′-CCGG GAATTCCAGCTCGTCCTTGGCCTGGC-3′. The amplified product was then cloned into the XbaI/EcoRI sites of the pcDNA3 vector (Invitrogen Corp.). For the generation of pcDNA3-CRT/E7, E7 was first amplified with a set of primers (5′-GGGGAATTCATGGAGATACACCTA-3′ and 5′-GGTG GATCCTTGAGAACAGATGG-3′) and cloned into the EcoRI/BamHI site of pcDNA3-CRT. For the generation of pcDNA3-GFP, the DNA fragment encoding the green fluorescent protein (GFP) was amplified with the primers 5′-AT CGGATCCATGGTGAGCAAGGGCGAGGAG-3′ and 5′-G GGAAGCTTTACTTGTACAGCTCGTCCATG-3′ and then cloned into the BamHI/HindIII cloning sites of pcDNA3 [28] . The accuracy of the DNA constructs was confirmed by DNA sequencing. The CRT/E7 DNA vaccine has previously been tested against a mock-DNA vaccine control [5] .
DNA vaccination by gene gun DNA-coated gold particles were prepared and gene gun particle-mediated DNA vaccination was performed according to a previously described protocol [29] . The coated gold particles (1 μg DNA/bullet) were delivered to the shaved abdominal region of the mice with a helium-driven gene gun (Bio-Rad Laboratories, Inc.) at a discharge pressure of 400 lb/in 2 . C57BL/6 mice (five per group) were immunized with 2 μg of the CRT/E7 or CRTE6E7L2 DNA vaccine and received four boosters with the same dose at 3-day intervals. Splenocytes were harvested on day 21 after the tumor challenge.
In vivo tumor treatment experiment
For in vivo tumor treatment, 1×10
5 TC-1 tumor cells per mouse were subcutaneously injected into the left flank area of 5-to 8-week-old C57BL/6 mice on day 0. After 5 days, the mice were divided into four groups (five per group), each receiving a different treatment regimen: group 1 received no treatment after the TC-1 tumor challenge, group 2 was treated daily with AR-42 by oral gavage (30 mg/kg body weight) for 10 days, group 3 was immunized with the DNA vaccine schedule as described above, and group 4 was both immunized and treated with AR-42. The AR-42 dosage was based on previous reports [14, [30] [31] [32] . Group 5 was immunized and treated with romidepsin intraperitoneally twice a week at 1.5 mg/kg per dose, similarly to what has been described previously [33] [34] [35] . Group 6 was immunized and treated with SAHA (IC 50 = 26 nM) per oral at 30 mg/kg per dose, similarly to what has been described previously [36] [37] [38] . Mice were monitored twice a week by inspection and palpation. AR-42 (NSC 736012) was a gift from Arno Therapeutics and is a novel hydroxamate-tethered phenylbutyrate derivative that has received IND approval from the FDA [14] . AR-42 was prepared as suspensions in vehicle (0.5 % methylcellulose and 0.1 % Tween-80, in sterile water). The CRTE6E7L2 DNA vaccine, which has been described previously [39] , was administered via gene gun in the amount of 2 μg/mouse beginning on day 5 at 3-day intervals for a total of four vaccinations.
Tetramer analysis of E7-specific CD8 + T cells
Peripheral blood samples (collected from the tail vein on day 21 after the tumor challenge) were depleted of red blood cells by ACK lysis and were stained with phycoerythrin (PE)-conjugated HPV16 H-2D b -RAHYNIVTF tetramer reagent (NCI). Tetramer staining was combined with surface staining using fluorescein isothiocyanate (FITC)-conjugated anti-CD8 (BD PharMingen). Cells were analyzed on a BD FACSCalibur collecting 30,000 events.
Intracellular cytokine staining and flow cytometry analysis
Pooled splenocytes from tumor-bearing mice that were treated with the various treatment regimens were harvested 7 days after the last treatment and incubated for 24 h with 1 μg/mL of the E7 peptide containing an MHC class I epitope (amino acids 49-57, RAHYNIVTF) [40] in the presence of GolgiPlug (BD Pharmingen, San Jose, CA). The stimulated splenocytes were then washed once with FACScan buffer and stained with PE-conjugated monoclonal rat anti-mouse CD8a (clone 53.6.7). Cells were subjected to intracellular cytokine staining using the Cytofix/Cytoperm kit according to the manufacturer's instruction (BD Pharmingen). Intracellular IFN-γ was stained with FITC-conjugated rat anti-mouse IFN-γ. All antibodies were purchased from BD Pharmigen. Flow cytometry analysis was done using FACSCalibur with CellQuest software (BD Bioscience).
MHC class I surface expression
In order to determine the in vitro expression of MHC class I molecules, A15 cells were incubated in a six-well plate 
In vitro cytotoxic T lymphocyte assays after AR-42 treatment
For the characterization of the E7 peptide presentation through the MHC class I molecules on TC-1 tumor cells treated with AR-42, intracellular cytokine staining for IFN-γ and flow cytometric analysis were performed to determine the activation of the E7-specific CD8 + T cell line [25] induced by TC-1 cells treated with or without 2.5 μM AR-42. TC-1 cells were incubated with E7-specific CD8
+ T cells at 1:1 ratio for 15 h. After incubation, cells were stained for CD8 and IFN-γ and analyzed with flow cytometry analysis. Luciferaseexpressing TC-1 cells [41] in the medium were seeded into 24-well round-bottomed plates (5×10 4 cells per well). The following day, the medium was replaced with 2 mL of fresh medium containing 0.5 μM AR-42 and incubated in a 5 % CO 2 atmosphere for 24 h at 37°C. The medium was then replaced, removing AR-42, and 1×10 6 E7-specific cytotoxic T lymphocytes from the T cell line described previously [25] were added to each well to serve as effector cells. TC-1 cells expressing luciferase were used as target cells. After incubation, D-luciferin (potassium salt; Xenogen Corp.) was added to each well at a concentration of 15 μg/mL in the medium. After 10 min, the cells were imaged with the Xenogen IVIS 200 system.
Statistical analysis
Exploratory statistical analyses based on data from multiple independent experiments or assays were conducted. Summary statistics such as the mean and SD were reported.
Comparisons between groups were made using Student's t test. Survival rates were estimated using the Kaplan-Meier method. Survival functions among the groups were compared using the log-rank test. Statistical analysis was performed using SPSS, version 17.0.
Results
AR-
+ T cell immune responses and have reduced tumor growth rates [5] . In this study, we examined whether AR-42 administered via oral gavage could enhance these effects. Mice were s.c. challenged with E7-expressing TC-1 tumor cells and began treatment 5 days later with AR-42 (daily for 10 days) and/or the CRT/E7 DNA vaccine (four times with 3-day intervals), as outlined in Fig. 1a . As shown in Fig. 1b , the tumors of the mice receiving both the DNA vaccine and AR-42 grew at a consistently reduced rate compared to the mice in the other treatment groups. Furthermore, this same group of mice survived significantly longer than the other groups of mice (Fig. 1c) . These data suggest that AR-42 is able to enhance the antitumor effects generated by the CRT/E7 DNA vaccine.
TC-1 tumor-bearing mice receiving both AR-42 and CRT/ E7 DNA generated greater numbers of E7-specific CD8 + T cells
On day 21 after tumor challenge, peripheral blood samples were collected from the tail vein of tumor-bearing mice in each treatment group, stained to identify E7-specific CD8 + T cells, and analyzed with flow cytometry. Mice receiving both the AR-42 and CRT/E7 DNA vaccines had more than twice the percentage of E7-specific CD8 + T cells among peripheral blood mononuclear cells (PBMCs) than the group receiving the DNA vaccine alone (17.78 vs. 7.89 %) and more than 20 times the group receiving AR-42 alone (17.78 vs. 0.83 %; Fig. 2a) . Additionally, splenocytes from the treated tumorbearing mice were harvested on day 21 and incubated with E7 peptide overnight. Splenocytes were stained for intracellular IFN-γ and then analyzed using flow cytometry. Mice receiving both the CRT/E7 DNA vaccine and AR-42 generated significantly more E7-specific, IFN-γ-producing CD8 + T cells (Fig. 2b) . Collectively, these data show that AR-42 treatment enhances the generation of E7-specific CD8 + T cells generated by the CRT/E7 DNA vaccine.
TC-1 tumor cells treated with AR-42 show increased expression levels MHC class I on the cell surface
To determine whether administration of AR-42 could increase the cell surface expression of MHC class I molecules, we used a TC-1 cell clone which was previously selected for the downregulation of MHC class I (A15 cells) [24] . A15 cells were incubated with AR-42 and the cell surface expression of MHC class I was analyzed using flow cytometry. As shown in Fig. 3 , A15 cells treated with AR-42 led to increased cell surface expression of MHC class I in vitro compared to untreated A15 cells.
AR-42 enhances the expression of DNA-encoded proteins in DNA-transfected dendritic cells
To understand whether AR-42 affects the expression level of the protein encoded by the DNA construct, which may play an important role in increasing antigen presentation in DCs, we transfected DC2.4 cells with a mammalian DNA expression vector encoding a marker protein, GFP (pcDNA-GFP). One day later, DNA-transfected DC2.4 cells were incubated with AR-42 at different concentrations for 24 h. The level of GFP expression in each group was measured using flow cytometry analysis. As shown in Fig. 4 , the GFP expression levels increased with increasing AR-42 concentration, suggesting that treatment with AR-42 can lead to the increased expression of DNA-encoded proteins.
Treatment of TC-1 cells with AR-42 induces significant in vitro cytotoxicity
To demonstrate whether TC-1 tumor cells treated with AR-42 can lead to increased HPV E7-specific cytotoxicity, we Fig. 5a , AR-42-treated TC-1 cells induced the activation of significantly more E7-specific CD8 + T cells compared to untreated TC-1 cells. These data suggest that TC-1 cells treated with AR-42 can lead to the enhanced presentation of E7 through the MHC class I pathway. However, further characterization of AR-42-treated TC-1 tumors did not reveal an upregulation of MHC class I expression (data not shown). These data imply that other potential mechanisms, such as increased E7 expression and/or enhanced E7 antigen processing, may account for the observed phenomenon.
In order to determine whether the enhanced presentation of E7 through the MHC class I pathway on TC-1 tumor cells could result in the increased susceptibility of TC-1 tumor cells to killing by E7-specific CD8 + T cells, we incubated E7-specific CD8 + T cells with luciferase-expressing TC-1 tumor cells with or without pretreatment with AR-42. Untreated luciferase-expressing TC-1 tumor cells were included as a control. As shown in Fig. 5b , luciferase-expressing TC-1 cells treated with AR-42 and incubated with E7-specific CD8 + T cells had a much greater decrease in luminescence, indicating greater cytotoxicity, than the luciferase-expressing TC-1 cells treated with either AR-42 or incubated with E7-specific CD8 + T cells alone. Taken together, these data suggest that TC-1 tumor cells treated with AR-42 are able to enhance MHC class I presentation, resulting in their increased susceptibility to killing by E7-specific CD8 + T cells.
AR-42 treatment in combination with CRT/E7 DNA vaccine generates a greater antitumor effect compared to various clinically available HDACi
Because there are two commercially available HDACi (romidepsin and SAHA), it is important to compare AR-42 with these HDACi for their ability to enhance the therapeutic antitumor effect generated by a therapeutic HPV DNA vaccine. Mice were s.c. challenged with TC-1 tumor cells and then were treated with different HDACi 5 days later, either romidepsin, SAHA, or AR-42, as indicated in Fig. 6a . Concurrent with HDACi administration, mice were treated with the CRT/E7 DNA vaccine. As shown in Fig. 6b , treatment with the CRT/E7 DNA vaccine and AR-42 generated the best therapeutic antitumor effect in TC-1 tumor-bearing mice, as measured by tumor volume, among all treatment groups. These data indicate that AR-42 is the ideal HDACi to be used in combination with a therapeutic HPV DNA vaccine in order to generate a potent therapeutic antitumor effect against E6/E7-expressing tumors. We observed similar results using the same treatment schedule with a different therapeutic HPV DNA vaccine encoding calreticulin linked to HPV-16 E6, E7, and L2 proteins (CRTE6E7L2) administered using a gene gun (Electronic supplementary material (ESM) Fig. 1a) . The CRTE6E7L2 DNA vaccine has been shown to generate a potent therapeutic antitumor effect against HPV-16 E6/E7-expressing tumors [39] . Again, AR-42 in combination with the CRTE6E7L2 DNA vaccine generated the most potent antitumor effect (ESM Fig. 1b) . Thus, these data have significant implications on future clinical translations of AR-42 as a potent anticancer drug.
Discussion
We demonstrated the ability of AR-42, an innovative HDACi, to enhance the potency of a DNA vaccine encoding CRT linked to the HPV oncogenic protein E7. Mice treated with AR-42 and the CRT/E7 DNA vaccine had reduced tumor growth and improved survival compared to mice treated with AR-42 alone or vaccine alone. Furthermore, combination treatment generated increased E7-specific CD8 + T cells and increased T cell-mediated cytotoxicity compared to treatment with AR-42 or the CRT/E7 DNA vaccine alone. More importantly, AR-42 was shown to be the ideal HDACi, compared to other commercially available HDACi, to be used in conjunction with a therapeutic HPV DNA vaccine to generate potent therapeutic antitumor effects. Taken together, AR-42 represents a particularly promising HDACi to be used in combination with clinical grade therapeutic HPV vaccines for the control of HPV-associated malignancies.
In the current study, treatment of TC-1 tumor cells with AR-42 alone appears to have more obvious cytotoxic effects in vitro (Fig. 5b ) compared to that in vivo (Fig. 1b) . This observation may be explained by multiple factors. For example, multiple aspects of the tumor microenvironment may inhibit the antitumor effects of treatment with AR-42 in vivo. In addition, the dose of AR-42 used in vivo may not be comparable to the dose used in vitro. These factors may account for the observed difference in the antitumor effects generated in vitro vs. in vivo.
In the current study, we have observed that AR-42 most effectively enhances the potency of therapeutic HPV DNA vaccines compared to SAHA and romidepsin. However, it is important to note that there are some limitations to comparing these HDACi, given that they were administered by different routes and regimens. The reported route of administration for romidepsin in a preclinical model is intraperitoneal injection [34, 35] , while that of AR-42 [14, [30] [31] [32] and SAHA [19] is oral gavage. While the dosages used for each HDACi were based on previous publications [14, [30] [31] [32] [33] [34] [35] [36] [37] [38] , the optimal dosages and regimens reported previously may not necessarily be applicable in the context of combinatorial treatment with DNA vaccines. Thus, it will be important to further optimize the doses and regimens of these HDACi, especially in studies involving combination treatments.
Encouraging preclinical data serve as an important foundation for future clinical trials for therapeutic HPVassociated cancer vaccines. Multiple HDACi and therapeutic HPV DNA vaccines have been tested independently in clinical trials [6, [42] [43] [44] . In addition, the HDACi Vorinostat (SAHA) is FDA-approved for the treatment of cutaneous manifestations of advanced primary cutaneous T cell lymphoma [16] . Additionally, a phase 1 trial of AR-42 treatment for multiple myeloma, chronic lymphocytic leukemia, and lymphoma is currently recruiting participants [45] . Thus, in order to identify the best HDACi for future clinical trials, it will be important to perform a head-to-head comparison for their ability to enhance the therapeutic effect of the HPV DNA vaccine. In addition, it will be important to determine an appropriate dosage and regimen for this treatment.
Several underlying mechanisms may account for the observed enhancement, by AR-42, of HPV antigen-specific CD8 + T cells and the antitumor effects generated by the CRT/E7 DNA vaccine administered intradermally via a gene gun. It has been shown that DNA vaccines administered using a gene gun can directly deliver the DNA to DCs in the skin [46] . Furthermore, previous studies have also demonstrated that AR-42 is able to enhance the expression of the protein encoded by the DNA vaccine [21] . As we show in Fig. 4 , treatment with AR-42 is able to enhance protein expression in DNA-transfected DCs. Taken together, the DNA-transfected DCs may become more capable of priming antigen-specific CD8 + T cells following treatment with AR-42. Additionally, we observed that tumor cells treated with AR-42 were more susceptible to antigen-specific CD8 + T cell-mediated killing (Fig. 5) . Consequently, treatment of tumor-bearing mice with AR-42 may make DNA-transfected DCs more effective in priming HPV antigen-specific CD8 + T cells as well as make tumor cells killed more easily by CD8 + T cells, resulting in a potent antitumor effect.
In summary, we found that the HDACi AR-42 could be used in conjunction with a therapeutic HPV DNA vaccine to improve therapeutic effects against HPV-associated cancer. It will be important to further determine the suitable HDACi and therapeutic HPV vaccine as well as the optimal regimen in preparation for clinical applications of this promising cervical cancer therapeutic approach. 
